CompanyRNANasdaqSan Diego, CA

Atrium Therapeutics

Atrium Therapeutics develops RNA therapeutics for cardiomyopathies using targeted delivery technology combining monoclonal antibodies with siRNA.

SEC EDGAR ClinicalTrials.gov atriumtherapeutics.com

SCHEDULE 13G/AAug 14Latest SEC filing

Aug 13Latest story

August 2026

Atrium Therapeutics clears IND for ATR 1072, activates first Corventis sites for PRKAG2 syndrome

Aug 13Quarterly updateATR-1072 Atrium Therapeutics

July 2026

Atrium Therapeutics recruiting for Phase 1/2 ATR 1072 trial in PRKAG2 Syndrome

Jul 31Trial updateATR-1072 Atrium Therapeutics